共 39 条
- [1] Krieger D.T., Amorosa L., Limick F., Cyproheptadine-induced remission of Cushing's disease, N Engl J Med, 293, pp. 893-896, (1975)
- [2] Miller J.W., Crapo L., The medical treatment of Cushing's syndrome, Endocrol Rev, 14, pp. 443-458, (1993)
- [3] Sonino N., Boscaro M., Medical therapy for Cushing's disease, Endocrinol Metab Clin North Am, 28, pp. 211-222, (1999)
- [4] Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P.A., International union pharmacology classification of receptors for 5-hydroxytryptamine (serotonin), Pharmacol Rev, 46, pp. 157-203, (1994)
- [5] Grossman A., What is the cause of Cushing's disease?, Clin Endocrinol, 36, pp. 451-452, (1992)
- [6] Biller M.K., Pathogenesis of pituitary Cushing's syndrome, Endocrinol Metab Clin North Am, 23, pp. 547-553, (1994)
- [7] Leysen J.E., Gommeren W., van Gompel P., Wynants J., Janssen P.F.M., Laduron P.M., Receptor-binding properties in vitro and in vivo of ritanserin, Mol Pharmacol, 27, pp. 600-611, (1985)
- [8] Awouters F., Niemegeers C.J.E., Megens A.A.H.P., Meert T.F., Janssen P.A.J., Pharmacological profile of ritanserin: A very specific central serotonin S<sub>2</sub>-antagonist, Drug Dev Res, 15, pp. 61-73, (1988)
- [9] Kristiansen K., Dahl S.G., Molecular modeling of serotonin, ketanserin, ritanserin and their 5HT<sub>2C</sub> receptor interactions, Eur J Pharmacol, 306, pp. 195-210, (1996)
- [10] Stefanski R., Goldberg S.R., Serotonin 5HT<sub>2</sub> receptor antagonists. Potential in the treatment of psychiatric disorders, CNS Drugs, 7, pp. 308-409, (1997)